* Eloxx Pharmaceuticals Inc ELOX.OQ reported a quarterly
adjusted loss of 20 cents per share for the quarter ended in
June. The mean expectation of four analysts for the quarter was
for a loss of 14 cents per share.
* Reported revenue was zero; analysts expected zero.
* Eloxx Pharmaceuticals Inc's reported EPS for the quarter was a
loss of 54 cents.
* The mean earnings estimate of analysts had risen by
about 19.1% in the last three months.
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company.
* Eloxx Pharmaceuticals Inc shares had fallen by 35.2% this
quarter and lost 67.6% so far this year.
* The company reported a quarterly loss of $35.06 million.
* Wall Street's median 12-month price target for Eloxx
Pharmaceuticals Inc is $3.55
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
This summary was machine generated August 16 at 09:29 p.m. All
figures in US dollars unless otherwise stated